- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NeoRx MoAb agent gets FDA panel's nod
A monoclonal antibody imaging agent under development by NeoRxcleared a major hurdle this month when a Food and Drug Administrationadvisory committee recommended the product for approval. The panel'smove puts NeoRx's Verluma, formerly known as OncoTrac,
A monoclonal antibody imaging agent under development by NeoRxcleared a major hurdle this month when a Food and Drug Administrationadvisory committee recommended the product for approval. The panel'smove puts NeoRx's Verluma, formerly known as OncoTrac, into positionto be the second monoclonal antibody-based imaging agent to reachthe market, after Cytogen's OncoScint CR/OV.
The FDA's Oncologic Drugs Advisory Committee recommended thatVerluma's product license application (PLA) be approved for theinitial staging of patients with biopsy-confirmed small-cell lungcancer. NeoRx hopes that Verluma, a technetium-labeled monoclonalantibody fragment, will prove cheaper and more useful than traditionalbatteries of tests for small-cell lung cancer, such as CT andbone scans. NeoRx representatives also say Verluma has a lowerHAMA (human anti-mouse antibody) response rate than other monoclonalantibody agents.
Seattle-based NeoRx has licensed North American rights forVerluma to Du Pont Merck Pharmaceutical (SCAN 10/26/94). BoehringerIngelheim manufactures Verluma for NeoRx.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
